Double Trouble: A New Drug Combination Decimates Liver Cancer Cells

Scientists have identified a potent synergistic effect between two types of drugs that could offer a new way to treat hepatocellular carcinoma (HCC), the most common type of liver cancer. The research focused on ChaC1, an enzyme that degrades glutathione—a vital molecule that acts as a chemical shield, protecting cells from oxidative stress.

Through rigorous screening, the team found that when ChaC1 is overexpressed, glutathione is depleted, rendering cancer cells extremely sensitive to a drug called auranofin. While auranofin triggers stress pathways within the cell, its lethality is massively amplified in the absence of glutathione. To replicate this effect without genetic manipulation, the researchers searched for drugs that naturally induce high levels of ChaC1. They discovered that proteasome inhibitors, a class of drugs already used in medicine, serve as potent inducers.

When the researchers treated HCC cells with both a proteasome inhibitor and auranofin, the combination caused 'catastrophic cell death'. This destruction was driven by a protein called DDIT4 and occurred independently of standard cell death routes like apoptosis, highlighting a mechanistically rational strategy for drug repurposing.